NVCR - 2 Under-the-Radar Biotech Stocks to Buy in 2022
Investing in biotechnology companies is both difficult and incredibly exciting. Watching as a company goes through the regulatory approval process, from a fledgling early-stage clinical trial biotech to an industry juggernaut, can be exhilarating.
While positive outcomes aren't guaranteed in clinical trials , let's look at two promising companies at different stages of development. Blueprint Medicines (NASDAQ: BPMC) has a promising drug candidate in phase 1/2 clinical trials , while Novocure (NASDAQ: NVCR) is looking to expand the labeling of its Optune device into larger markets. If results continue to be positive, both healthcare companies could be in for a multibillion-dollar windfall.
After a sluggish past few years, including a 37% slump in its stock price since the start of the year, Blueprint Medicines now looks ready to charge ahead. Its primary focus has been mastocytosis, a disease in which certain types of cells release substances that can cause signs and symptoms similar to those of an allergic reaction -- and result in severe inflammation and organ damage.
For further details see:
2 Under-the-Radar Biotech Stocks to Buy in 2022